تقرير
أعرض في EDS

Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia.

التفاصيل البيبلوغرافية
العنوان: Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia.
المؤلفون: Locatelli F; Department of Pediatric Hematology/Oncology and of Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Sapienza University of Rome, Rome, Italy. franco.locatelli@opbg.net., Whitlock JA; The Hospital for Sick Children/University of Toronto, Toronto, ON, Canada., Peters C; St. Anna Children's Hospital, Vienna, Austria., Chen-Santel C; Department of Paediatric Oncology/Hematology/BMT, Charité Universitäts Medizin Berlin, Berlin, Germany., Chia V; Amgen Inc, Thousand Oaks, CA, USA., Dennis RM; Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA., Heym KM; Cook Children's Medical Center, Fort Worth, TX, USA., Katz AJ; Amgen Inc, Thousand Oaks, CA, USA., Kelsh MA; Amgen Inc, Thousand Oaks, CA, USA.; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA., Sposto R; Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA., Tu H; Amgen Inc, Thousand Oaks, CA, USA., Tuglus CA; Amgen Inc, Thousand Oaks, CA, USA., Verma A; Primary Children's Hospital, Pediatric Hematology/Oncology, University of Utah, Salt Lake City, UT, USA., Vinti L; Department of Pediatric Hematology/Oncology and of Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Sapienza University of Rome, Rome, Italy., Wilkes JJ; Center for Clinical and Translational Research, Seattle Children's Hospital and Research Institute, Seattle, WA, USA.; Department of Pediatrics, University of Washington, Seattle, WA, USA., Zubarovskaja N; St. Anna Children's Hospital, Vienna, Austria., Zugmaier G; Amgen Research, Munich, Germany., von Stackelberg A; Department of Paediatric Oncology/Hematology/BMT, Charité Universitäts Medizin Berlin, Berlin, Germany., Sun W; City of Hope National Medical Center, Pediatric Hematology Oncology, Duarte, CA, USA.; Janssen Pharmaceutica, Beerse, Belgium.
المصدر: Leukemia [Leukemia] 2020 Sep; Vol. 34 (9), pp. 2473-2478. Date of Electronic Publication: 2020 Feb 24.
نوع المنشور: Letter; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE
أسماء مطبوعة: Publication: 2000- : London : Nature Publishing Group, Specialist Journals
Original Publication: [Baltimore, Md.] : Williams & Wilkins, [c1987-
مواضيع طبية MeSH: Philadelphia Chromosome*, Antibodies, Bispecific/*therapeutic use , Antineoplastic Agents/*therapeutic use , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy, Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Male ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Recurrence
References: Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N. Engl J Med. 2012;366:1371–81. (PMID: 10.1056/NEJMoa1110169)
Locatelli F, Schrappe M, Bernardo ME, Rutella S. How i treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012;120:2807–16. (PMID: 10.1182/blood-2012-02-265884)
Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-the all-sct-bfm-2003 trial. J Clin Oncol. 2015;33:1265–74. (PMID: 10.1200/JCO.2014.58.9747)
von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, et al. Phase i/phase ii study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34:4381–9. (PMID: 10.1200/JCO.2016.67.3301)
Hijiya N, Thomson B, Isakoff MS, Silverman LB, Steinherz PG, Borowitz MJ, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011;118:6043–9. (PMID: 10.1182/blood-2011-08-374710)
Leung AW, Vincent L, Chiang AK, Lee AC, Cheng FW, Cheuk DK, et al. Prognosis and outcome of relapsed acute lymphoblastic leukemia: a Hong Kong pediatric hematology and oncology study group report. Pediatr Blood Cancer. 2012;59:454–60. (PMID: 10.1002/pbc.24162)
Locatelli F, Testi AM, Bernardo ME, Rizzari C, Bertaina A, Merli P, et al. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol. 2009;147:371–8. (PMID: 10.1111/j.1365-2141.2009.07882.x)
Reismuller B, Attarbaschi A, Peters C, Dworzak MN, Potschger U, Urban C, et al. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in austria—a population-based report of the austrian berlin-frankfurt-munster (bfm) study group. Br J Haematol. 2009;144:559–70. (PMID: 10.1111/j.1365-2141.2008.07499.x)
Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, et al. Outcome of children with multiply relapsed b-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia. 2018;32:2316–25. (PMID: 10.1038/s41375-018-0094-0)
International Conference On Harmonisation Expert Working Group. Ich harmonised tripartite guideline: Choice of control group and related issues in clinical trials e10. Accessed 5 Oct 2018. https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf .
Gokbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, et al. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J. 2016;6:e473. (PMID: 10.1038/bcj.2016.84)
Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004;23:2937–60. (PMID: 10.1002/sim.1903)
Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55. (PMID: 10.1093/biomet/70.1.41)
المشرفين على المادة: 0 (Antibodies, Bispecific)
0 (Antineoplastic Agents)
4FR53SIF3A (blinatumomab)
تواريخ الأحداث: Date Created: 20200226 Date Completed: 20201118 Latest Revision: 20210209
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7449874
DOI: 10.1038/s41375-020-0770-8
PMID: 32094465
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-5551
DOI:10.1038/s41375-020-0770-8